香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 中國上海 2025年11月13日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-1 ...

Core Insights - The article highlights the top and bottom performing AH share premium rates as of November 12, with Northeast Electric (00042) leading at 847.37% and Ningde Times (03750) at -15.85% [1][2] Summary by Category Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 847.37% with H-share priced at 0.285 HKD and A-share at 2.25 CNY [1] - Hongye Futures (03678) follows with a premium rate of 266.57%, H-share at 3.590 HKD and A-share at 10.99 CNY [1] - Zhejiang Shibao (01057) ranks third with a premium rate of 264.95%, H-share at 4.650 HKD and A-share at 14.17 CNY [1] Bottom AH Share Premium Rates - Ningde Times (03750) shows a negative premium rate of -15.85%, with H-share at 550.000 HKD and A-share at 386.38 CNY [1] - China Merchants Bank (03968) has a premium rate of -1.59%, H-share at 52.250 HKD and A-share at 42.93 CNY [1] - Heng Rui Pharmaceutical (01276) has a premium rate of 3.59%, H-share at 71.800 HKD and A-share at 62.1 CNY [1] Top AH Share Deviation Values - Zhejiang Shibao (01057) leads with a deviation value of 27.23% [1] - Hongye Futures (03678) has a deviation value of 25.25% [1] - Sinopec Oilfield Service (01033) follows with a deviation value of 20.25% [1] Bottom AH Share Deviation Values - Andeli Juice (02218) has the lowest deviation value at -25.93% [1] - China Life (02628) follows with -19.73% [1] - CNOOC Services (02883) has a deviation value of -13.96% [1]

Group 1 - The company, Heng Rui Pharmaceutical (01276.HK), announced a share buyback plan on November 11, 2025, involving an expenditure of RMB 9.1526 million to repurchase 150,000 A shares [1] - The buyback price per share is set between RMB 61.01 and RMB 61.07 [1]

Core Viewpoint - Heng Rui Medicine (01276) announced a share buyback plan, intending to repurchase 150,000 A-shares at a cost of 9.1526 million yuan, scheduled for November 11, 2025 [1] Company Summary - The company is engaging in a share repurchase, which indicates a strategy to enhance shareholder value and potentially signal confidence in its future performance [1] - The total amount allocated for the buyback is 9.1526 million yuan, reflecting the company's commitment to returning capital to shareholders [1]

表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 呈交日期： 2025年11月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總 ...

Core Viewpoint - Heng Rui Medicine (01276) announced a share buyback of 60,000 A-shares for a total expenditure of RMB 3.6684 million on November 10, 2025, with a buyback price range of RMB 61.00 to 61.31 per share [1] Group 1 - The company plans to repurchase shares to potentially enhance shareholder value [1] - The total amount allocated for the buyback is RMB 3.6684 million [1] - The number of shares to be repurchased is 60,000 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年11月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包 ...

Core Insights - The article highlights the current AH premium rates of various stocks, with Northeast Electric (00042) leading at 864.29% [1] - The article also identifies the stocks with the lowest AH premium rates, with China Merchants Bank (03968) showing a slight negative premium of -0.54% [1] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042): 864.29% - Hongye Futures (03678): 261.08% - Sinopec Oilfield Service (01033): 253.16% [1] - The bottom three stocks with the lowest AH premium rates are: - China Merchants Bank (03968): -0.54% - Heng Rui Medicine (01276): 4.02% - Midea Group (00300): 6.04% [1] Deviation Value Rankings - The stocks with the highest deviation values are: - Junsheng Electronics (00699): 85.91% - Silis (09927): 43.66% - Northeast Electric (00042): 30.58% [1] - The stocks with the lowest deviation values are: - China Life (02628): -14.16% - CNOOC Services (02883): -12.32% - Ganfeng Lithium (01772): -11.28% [1]

Major Events - LeShuShi (02698) received a subscription rate of 1813.77 times for its public offering in Hong Kong, with an expected listing date of November 10 [1] - Zhongwei New Materials (02579) is in the process of an IPO from November 7 to November 12, with an expected listing on November 17 [1] - Baili Tianheng (02615) is also conducting an IPO from November 7 to November 12, with a listing expected on November 17 [1] - Haohai Biological Technology (06826) plans to acquire the remaining 20% stake in Shenzhen New Industry Ophthalmic Technology Co., Ltd. for 74 million yuan [1] - Weili Zhibo-B (09887) has been included in the MSCI Global Small Cap Index [1] - Heng Rui Medicine (01276) has received clinical trial approval notifications for HRS-2430 injection and SHR-4610 injection [1] Financial Data - Fuzhikang Group (02038) anticipates a year-on-year revenue growth of approximately 15% and significant improvement in financial performance [1] - Boya Interactive (00434) expects a year-on-year increase of approximately 105% to 115% in profit attributable to owners for the first nine months [1] - Longfor Group (00960) reported a total contract sales amount of 55.75 billion yuan for the first ten months [1] - Longyuan Power (00916) completed a total power generation of 62.1519 million megawatt-hours in the first ten months, representing a year-on-year decrease of 0.94% [1]

Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-4610 injection, an innovative anti-tumor drug developed by the company [1] Group 1 - SHR-4610 injection has shown good anti-tumor activity in preclinical animal models and is intended for the treatment of advanced solid tumors [1] - The total research and development investment for the SHR-4610 injection project has reached approximately 7.36 million yuan [1]